Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene

NCT03780257 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa
Usher Syndrome Type 2
Deaf Blind
Retinal Disease
Eye Diseases
Eye Diseases, Hereditary
Eye Disorders Congenital
Vision Disorders

Interventions

DRUG: QR-421a
OTHER: Sham-procedure (dose cohort 1&2 only)

Sponsor

ProQR Therapeutics